Juventas Therapeutics
Pioneering regenerative therapies for life-threatening diseases with a robust clinical pipeline and a strong foundation in collaboration and innovation.
Pioneering regenerative therapies for life-threatening diseases with a robust clinical pipeline and a strong foundation in collaboration and innovation.
Juventas Therapeutics is a clinical-stage biotechnology company, founded in 2007, that is dedicated to developing regenerative therapies for life-threatening diseases. With an exclusive license from the Cleveland Clinic, the company has progressed from concept to mid-stage clinical trials. Its investors, including Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co., have provided significant support. Additionally, Juventas Therapeutics has received non-dilutive grants from the Ohio Third Frontier-funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center, and Center for Stem Cell & Regenerative Medicine.
The most recent investment in the company was a $13.50M Series B investment on 12 May 2015, with POSCO Venture Capital and Green Cross as the major investors.
Juventas Therapeutics' commitment to pioneering regenerative therapies for life-threatening diseases has attracted notable support, positioning it as a promising player in the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $13.50M | 2 |
|
12 May 2015 |
| Venture Round | $5.00M | - | 20 Nov 2013 | |
| Series B | $22.20M | 8 |
|
16 Jul 2012 |
| Series A | $7.72M | - | 23 Oct 2008 | |
| Pre Seed Round | $300.00K | - | 30 Sep 2008 |
No recent news or press coverage available for Juventas Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
